CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study is to investigate the therapeutic efficacy and side effect of chidamide,
decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid
leukemia
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University